Correlation Between Achilles Therapeutics and Alx Oncology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Achilles Therapeutics and Alx Oncology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Achilles Therapeutics and Alx Oncology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Achilles Therapeutics PLC and Alx Oncology Holdings, you can compare the effects of market volatilities on Achilles Therapeutics and Alx Oncology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Achilles Therapeutics with a short position of Alx Oncology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Achilles Therapeutics and Alx Oncology.

Diversification Opportunities for Achilles Therapeutics and Alx Oncology

-0.54
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Achilles and Alx is -0.54. Overlapping area represents the amount of risk that can be diversified away by holding Achilles Therapeutics PLC and Alx Oncology Holdings in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Alx Oncology Holdings and Achilles Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Achilles Therapeutics PLC are associated (or correlated) with Alx Oncology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Alx Oncology Holdings has no effect on the direction of Achilles Therapeutics i.e., Achilles Therapeutics and Alx Oncology go up and down completely randomly.

Pair Corralation between Achilles Therapeutics and Alx Oncology

Given the investment horizon of 90 days Achilles Therapeutics PLC is expected to generate 0.43 times more return on investment than Alx Oncology. However, Achilles Therapeutics PLC is 2.33 times less risky than Alx Oncology. It trades about 0.15 of its potential returns per unit of risk. Alx Oncology Holdings is currently generating about -0.18 per unit of risk. If you would invest  118.00  in Achilles Therapeutics PLC on December 28, 2024 and sell it today you would earn a total of  30.00  from holding Achilles Therapeutics PLC or generate 25.42% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthVery Weak
Accuracy91.8%
ValuesDaily Returns

Achilles Therapeutics PLC  vs.  Alx Oncology Holdings

 Performance 
       Timeline  
Achilles Therapeutics PLC 

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Achilles Therapeutics PLC are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical indicators, Achilles Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point.
Alx Oncology Holdings 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Alx Oncology Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Achilles Therapeutics and Alx Oncology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Achilles Therapeutics and Alx Oncology

The main advantage of trading using opposite Achilles Therapeutics and Alx Oncology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Achilles Therapeutics position performs unexpectedly, Alx Oncology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alx Oncology will offset losses from the drop in Alx Oncology's long position.
The idea behind Achilles Therapeutics PLC and Alx Oncology Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Complementary Tools

Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance